Position in AKTS
as of Jun 30, 2026
· filed Jul 6, 2026
Position Value
$934
New position
Shares Held
29
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#9
of 10 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Jun 30, 2026CoreCap Advisors, LLC holds $2,312,000 across 78 Biotechnology names. AKTS ranks #44 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
6,755 | $367,539 | |
| 2 | MRNA |
Moderna, Inc.
|
4,595 | $321,787 | |
| 3 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
3,000 | $244,530 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
442 | $219,554 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
315 | $196,415 | |
| 6 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
280 | $150,346 | |
| 7 | ANIX |
Anixa Biosciences Inc
|
52,020 | $145,656 | |
| 8 | LGND |
Ligand Pharmaceuticals Inc
|
428 | $135,286 |
All Filings in AKTS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $934 | 29 | Shares | Sole | 2026-07-06 | |
| No filing history on record for this holder in this stock. | ||||||